Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant drop in short interest in October. As of October 15th, there was short interest totaling 292,400 shares, a drop of 49.6% from the September 30th total of 579,800 shares. Based on an average daily volume of 287,100 shares, the days-to-cover ratio is currently 1.0 days. Currently, 6.4% of the company’s stock are short sold. Currently, 6.4% of the company’s stock are short sold. Based on an average daily volume of 287,100 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Finally, Ascendiant Capital Markets lifted their target price on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a report on Tuesday, September 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vivos Therapeutics presently has an average rating of “Hold” and a consensus target price of $4.92.

Vivos Therapeutics Stock Performance

Shares of Vivos Therapeutics stock opened at $2.58 on Friday. The firm’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $3.51. The stock has a market capitalization of $19.35 million, a price-to-earnings ratio of -1.54 and a beta of 6.90. Vivos Therapeutics has a 12 month low of $1.98 and a 12 month high of $7.95. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Tuesday, August 19th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The business had revenue of $3.82 million during the quarter, compared to analyst estimates of $3.37 million. Vivos Therapeutics had a negative net margin of 99.49% and a negative return on equity of 232.76%. As a group, equities analysts forecast that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Hedge Funds Weigh In On Vivos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VVOS. XTX Topco Ltd purchased a new position in Vivos Therapeutics in the 2nd quarter valued at $65,000. Cutter & CO Brokerage Inc. grew its position in Vivos Therapeutics by 28.9% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 49,100 shares of the company’s stock valued at $140,000 after buying an additional 11,000 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the 2nd quarter valued at $220,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.